Artificial Intelligence for Evidence Synthesis of Emerging Biologics to Improve Skeletal Health in Osteogenesis Imperfecta: Systematic Review and Meta-Analysis - Report - MDSpire
Advertisement
Artificial Intelligence for Evidence Synthesis of Emerging Biologics to Improve Skeletal Health in Osteogenesis Imperfecta: Systematic Review and Meta-Analysis
Clinical Report: Utilizing Artificial Intelligence for Systematic Review and Meta-Analysis of New Biologics Aimed at Enhancing Bone Health in Osteogenesis Imperfecta
Background
Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility and associated complications, leading to significant lifelong disability. Current treatments primarily focus on symptomatic relief with bisphosphonates, which are less effective in certain patient populations. The emergence of biologics presents new therapeutic avenues, but their clinical efficacy and safety require thorough investigation.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
OI has an estimated incidence of 1 in 15,000 to 20,000 live births.
Current therapies, including bisphosphonates, are primarily palliative and less effective in adults and severe phenotypes.
Emerging biologics target specific molecular pathways in bone remodeling, potentially offering improved efficacy.
Existing systematic reviews of biologics are limited by narrow drug scope and variability in study design.
AI can assist in the systematic review process, but current implementations have methodological limitations.
Clinical Implications
The findings emphasize the need for updated systematic reviews to inform clinical decision-making regarding biologics for OI. Incorporating AI into the review process may enhance efficiency but requires careful consideration of methodological rigor.
Conclusion
The systematic review and meta-analysis of biologics for OI highlight the potential of AI in improving the review process, while also underscoring the need for comprehensive evaluations of these emerging therapies.
by Chengfei Li, Zonglin Dai, Wing Chung Tang, Zesen Gao, Vivien Kin Yi Chan, Mariana Ramirez-Posada, Jiyeong Kim, Eleni Linos, CL Cheung, Ian Chi Kei Wong, Dong Dong, Michael To, Dawn Craig, Xue Li
High-revision-rate surgeons saw a late revision signal after adopting robotic-assisted total knee arthroplasty, despite no overall reduction in revision rates or failure modes.
